This mutation, corresponding to C1156Y in full‐length ALK, is near the αC helix domain and was first described in a crizotinib‐resistant ALK+ NSCLC patient26 causing resistance via conformational changes that alter kinase activity in line with in vivo results (Figure 3G).27 The gene discussed is ALK; the disease is non-small cell lung carcinoma.